ALLO Allogene Therapeutics Inc.

27.05
+0.65  (+2%)
Previous Close 26.4
Open 26.33
Price To Book 4.82
Market Cap 3,287,638,606
Shares 121,539,320
Volume 358,565
Short Ratio
Av. Daily Volume 515,105

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 update at ASH December 3, 2018 noted 86% CR/CRi.
UCART19 (PALL)
Acute lymphoblastic leukemia (ALL)
Phase 1 update 2019.
UCART19 - CALM
Refractory B-cell Acute Lymphoblastic Leukaemia
Phase 1/2 trial to be initiated in 2H 2019.
ALLO-715
Multiple myeloma
Phase 1 initial data due 1H 2020.
ALLO-501 - ALPHA
Non-Hodgkin lymphoma (NHL)

Latest News

  1. Senator Dianne Feinstein’s Husband Sold Nvidia Stock, Bought FireEye
  2. Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
  3. Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
  4. Allogene Therapeutics Announces June 2019 Investor Conference Schedule
  5. Allogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript
  6. Allogene Therapeutics: 1Q Earnings Snapshot
  7. Allogene Therapeutics Reports First Quarter 2019 Financial Results
  8. 2 Big Biotech Stock Upgrades: Can They Reach These Targets?
  9. Allogene Therapeutics Announces Expansion of Scientific Advisory Board
  10. Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
  11. Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
  12. Allogene Therapeutics Announces April 2019 Investor Conference Schedule 
  13. Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
  14. All You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial Health
  15. Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  16. Allogene Therapeutics, Inc. to Host Earnings Call
  17. Meet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space
  18. Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
  19. 4 Disruptive Healthcare Stocks You've Never Heard Of
  20. Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule